In the pooled data from the pivotal STEP licensing trials (STEP 2, 3 and 4), 3% of adults on semaglutide 2.4 mg lost a measurable amount of hair, compared with 1% on placebo
In April 2025, Blue Cross Blue Shield of Massachusetts (BCBSMA), the states largest insurer, announced that it would end coverage of GLP-1 medications for obesity treatment beginning in January 2026, a move that will significantly restrict access for Boston residents who depend on these treatments
Pathophysiology, clinical presentation, and treatment of psoriasis: a review
Its pain-free and safe
Join LifeMD today and experience amazing healthcare, discounted labs and prescription medications plus around-the-clock access to medical guidance
Important safety considerations : If your pharmacy dispenses a compounded tirzepatide preparation, vial formulation, or product from an unfamiliar manufacturer, consult your pharmacist immediately